LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

GT Biopharma, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERGTBP
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / GTBP COVERAGE

What’s moving GT Biopharma, Inc. now

Current reporting with the operating signal separated from the noise.

01
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Investors are testing whether GT Biopharma, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest GTBP filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-15 · Period 2026-03-31SEC ↗10-Q/AQuarterly financial reportFiled 2026-03-06 · Period 2025-06-30SEC ↗10-KAnnual financial reportFiled 2026-03-02 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-12 · Period 2026-06-08SEC ↗8-KMaterial company eventFiled 2026-05-22 · Period 2026-05-20SEC ↗8-KMaterial company eventFiled 2026-04-07 · Period 2026-04-03SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-07-02 · Period 2026-07-02SEC ↗PRE 14AOfficial SEC filingFiled 2026-06-18 · Period 2026-06-18SEC ↗
EARNINGS / QUARTERLY TRACKER

GT Biopharma, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.